List of Excipients in Branded Drug DANTRIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Health USA LLC	DANTRIUM	dantrolene sodium	42023-123	MANNITOL
Par Health USA LLC	DANTRIUM	dantrolene sodium	42023-123	SODIUM HYDROXIDE
Endo USA Inc	DANTRIUM	dantrolene sodium	42023-124	FD&C YELLOW NO. 6
Endo USA Inc	DANTRIUM	dantrolene sodium	42023-124	GELATIN
Endo USA Inc	DANTRIUM	dantrolene sodium	42023-124	LACTOSE MONOHYDRATE
Endo USA Inc	DANTRIUM	dantrolene sodium	42023-124	MAGNESIUM STEARATE

Dantrium Excipient Strategy and Commercial Opportunities: Dantrolene Sodium Formulations, Generic Entry and Hospital Market Analysis

Last updated: September 24, 2026

Dantrium is a dantrolene sodium product used primarily for malignant hyperthermia and, in oral form, for chronic spasticity. Its commercial opportunity is driven less by new molecular patents than by formulation performance, hospital readiness, supply reliability, administration speed and regulatory differentiation. Oral capsules offer a conventional generic pathway. Intravenous dantrolene offers higher-value opportunities in rapid reconstitution, reduced preparation burden, emergency stock management and differentiated packaging.

What is Dantrium and which formulations are commercially relevant?

Dantrium contains dantrolene sodium, a direct skeletal-muscle relaxant that reduces calcium release from the sarcoplasmic reticulum through the ryanodine receptor pathway. The product has two principal dosage-form strategies:

Product category	Active ingredient	Primary use	Commercial characteristics
Dantrium capsules	Dantrolene sodium	Chronic spasticity	Genericized oral product with price competition
Dantrium intravenous product	Dantrolene sodium	Malignant hyperthermia emergency treatment	Hospital-critical product with higher value attached to speed, availability and preparation
Competing rapid-delivery products	Dantrolene sodium	Malignant hyperthermia	Differentiation through concentration, vial size, reconstitution time and workflow

FDA labeling identifies Dantrium capsules in multiple strengths, including 25 mg, 50 mg and 100 mg. Intravenous dantrolene products historically have used a lyophilized or highly soluble powder requiring reconstitution before administration.[1]

The intravenous segment is commercially distinct from the capsule market. Hospitals must maintain sufficient dantrolene inventory under malignant hyperthermia preparedness standards, even though demand is episodic. This creates recurring revenue from emergency stock replacement, expiration management and institutional purchasing.

What excipients are used in Dantrium products?

The exact excipient profile depends on the dosage form and manufacturer. Oral capsules generally use conventional solid-dose excipients, while intravenous products require excipients that support rapid dissolution, chemical stability and safe parenteral administration.

Oral capsule excipient strategy

Dantrium capsule formulations have historically used combinations of:

• Lactose or another diluent
• Corn starch or other disintegrant
• Magnesium stearate as a lubricant
• Talc or flow-control material
• Capsule-shell gelatin
• Approved colorants for strength identification

The commercial purpose of these excipients is functional rather than therapeutic. The formulation must provide:

1. Consistent powder fill weight.
2. Rapid capsule opening and drug release.
3. Acceptable content uniformity at low strength.
4. Mechanical stability during distribution.
5. Differentiated capsule colors by strength.
6. Manageable raw-material cost.

Dantrolene sodium is a relatively high-dose active pharmaceutical ingredient in the 100 mg capsule. Excipient selection therefore affects capsule size, fill density and patient acceptability. A low-density blend can increase capsule volume and manufacturing cost. Excessive lubrication can slow dissolution, particularly if magnesium stearate concentration or blending time is not controlled.

Potential oral excipient opportunities

The most practical commercial opportunities are incremental:

• Lactose-free capsules for patients with lactose intolerance or institutional procurement preferences.
• Low-moisture formulations to improve stability during distribution.
• Direct-compression or improved-flow blends that reduce manufacturing variability.
• Smaller capsule dimensions through higher-density excipient systems.
• Color-free or simplified-color capsules for markets with excipient restrictions.
• Low-dust formulations for safer manufacturing and improved content uniformity.
• Modified-release products for chronic spasticity, if clinical and regulatory value can be demonstrated.

A lactose-free formulation could support a differentiated label under a 505(b)(2) strategy if the formulation provides a clinically or operationally meaningful advantage. A conventional lactose substitution alone would likely face limited commercial protection unless linked to a specific patient population, tolerability benefit or manufacturing advantage.

What excipients are used in intravenous dantrolene products?

Intravenous dantrolene places greater demands on excipient selection. The formulation must dissolve quickly after reconstitution, remain chemically stable in the vial and minimize particulate or precipitation risk.

Traditional intravenous dantrolene products have used mannitol and pH adjustment with sodium hydroxide. The vial is reconstituted with sterile water for injection before administration. The high mannitol content supports the formulation but also increases the volume and physical handling requirements of emergency preparation.[1]

Key formulation variables include:

Variable	Commercial impact
Mannitol concentration	Affects cake structure, osmolality and reconstitution behavior
pH	Influences solubility, stability and injection tolerability
Vial fill weight	Determines dose capacity and emergency inventory burden
Reconstitution volume	Directly affects preparation time and staff workload
Container closure	Controls moisture ingress and shelf life
Lyophilization cycle	Determines cake integrity, residual moisture and dissolution speed
Preservative status	Affects suitability for emergency intravenous use

The primary value driver is not excipient novelty alone. It is the total emergency-use profile: time to prepare, number of vials, amount of sterile water required, storage requirements, shelf life and risk of preparation error.

What formulations are protected by Dantrium-related intellectual property?

Dantrolene sodium is an established active ingredient with extensive generic competition. The original active-ingredient and early product patents are not expected to provide a meaningful barrier to ordinary oral generic entry. Commercial protection is more likely to arise from:

• Specific intravenous formulation compositions.
• Lyophilized cake structures.
• Reduced-volume or high-concentration formulations.
• Reconstitution methods.
• Vial and transfer-device configurations.
• Emergency dosing systems.
• Stability-enhancing packaging.
• Manufacturing processes.
• Combination products incorporating delivery devices.

A formulation patent must distinguish the product through defined composition ranges, measurable performance or a non-obvious manufacturing process. Broad claims covering dantrolene sodium with standard diluents or buffers are vulnerable to validity and obviousness challenges.

How strong is the Dantrium patent estate?

The estate is stronger for differentiated intravenous delivery than for conventional capsules. Oral dantrolene is exposed to ANDA competition because the active ingredient, dosage forms and basic excipient systems are well established.

The more defensible claim areas are:

1. Rapid-reconstitution formulations.
2. Lower-volume emergency products.
3. Improved stability under hospital storage conditions.
4. Integrated kits that reduce preparation steps.
5. Device-enabled delivery systems.
6. Manufacturing controls that produce a distinctive physical form.

Patent strength depends on claim scope, clinical relevance and the ability to show a meaningful improvement over earlier dantrolene products. A patent that only substitutes one common excipient for another is generally less commercially durable than a patent tied to materially faster dissolution, fewer preparation steps or improved shelf stability.

When does Dantrium lose exclusivity?

Dantrium’s original exclusivity has expired. The principal commercial issue is therefore not the loss of original brand exclusivity but the status of current formulation, manufacturing and device rights.

Protection category	Dantrium position
Active-ingredient exclusivity	Expired
Conventional oral generic pathway	Available in principle through ANDA approval
Hospital intravenous formulation	Potentially differentiated by formulation, device or product-specific rights
Orphan-drug exclusivity	Not generally the primary barrier for established dantrolene products
Pediatric exclusivity	No broad current barrier should be assumed without a product-specific FDA record
Trademark protection	May continue independently of patent rights

FDA approval under section 505(j) is the likely pathway for a conventional generic capsule that matches the reference product in active ingredient, strength, dosage form, route and labeling, subject to the statutory requirements. A materially different intravenous formulation may require a 505(b)(2) application.[2]

What is the Orange Book status of Dantrium?

The FDA Orange Book is the relevant source for listed reference products, patents, exclusivity and therapeutic-equivalence evaluations. Orange Book treatment can differ between capsule strengths and intravenous products, and listing status can change with product discontinuation, manufacturer changes or patent certifications.[3]

For commercial planning, an applicant should distinguish among:

• The reference-listed drug.
• Generic products with A-rated therapeutic equivalence.
• Patents listed for the reference product.
• Drug substance, drug product and method-of-use patents.
• Discontinued products that remain relevant to reference-product selection.
• Current marketing status of the branded product.

A Paragraph IV filing could challenge any listed patent that is considered invalid, unenforceable or not infringed. For an old active ingredient, the more realistic Paragraph IV targets would be later formulation or delivery patents rather than original dantrolene composition claims.

Which companies are challenging Dantrium?

The generic dantrolene market has historically included multiple manufacturers and distributors. Public FDA materials identify approved dantrolene sodium products, but market participation changes through product discontinuations, contract-manufacturing arrangements and distributor substitutions.

The most relevant competitive groups are:

• Established generic manufacturers supplying dantrolene capsules.
• Hospital injectable suppliers.
• Specialized emergency-medicine manufacturers.
• Companies offering rapid-reconstitution intravenous dantrolene.
• Contract manufacturers with sterile lyophilization capacity.

A current company-by-company Paragraph IV assessment cannot be reliably inferred from product labels alone. Paragraph IV activity must be tied to a specific Orange Book-listed patent, ANDA applicant and litigation docket.

What patent litigation affects Dantrium?

The main litigation risks are likely to arise from later intravenous formulations rather than the original oral product. Relevant causes of action may include:

• Patent infringement claims against an ANDA applicant.
• Declaratory judgment actions involving formulation patents.
• Trademark disputes over Dantrium branding.
• Trade-secret disputes involving lyophilization or manufacturing processes.
• Contract disputes between brand owners and manufacturing partners.

For a conventional oral capsule, litigation risk is generally lower because multiple generic formulations can be designed around basic excipient claims. For an intravenous product, litigation risk increases when a formulation combines a specific excipient ratio, lyophilization process and emergency-use performance claim.

No settlement terms should be assumed without a filed agreement, consent judgment or court record. A settlement could restrict launch timing, manufacturing sources, product strengths or authorized-generic rights.

What commercial opportunities exist for Dantrium excipients and reformulation?

1. Rapid-reconstitution intravenous product

The strongest opportunity is a product that reduces preparation time and labor. A formulation using a higher active concentration, optimized cake structure or improved solubilization system could reduce vial count and sterile-water handling.

The product would compete on:

• Minutes saved before administration.
• Number of vials needed for a standard emergency dose.
• Reconstitution volume.
• Ease of shaking or mixing.
• Stability after reconstitution.
• Compatibility with hospital emergency protocols.

2. Hospital inventory and emergency kits

A manufacturer can create value through packaged readiness rather than through the drug alone. Commercial configurations may include:

• Preassembled malignant hyperthermia carts.
• Dantrolene kits with sterile water and transfer components.
• Barcoded inventory management.
• Expiration monitoring.
• Replacement programs for hospital stock.
• Dose calculators and preparation aids.

These services can support contracting even when the active ingredient is generic.

3. Oral capsule differentiation

Oral reformulation has lower upside but can target specific procurement and adherence needs:

• Lactose-free product.
• Smaller capsules.
• Strength-color standardization.
• Blister packaging.
• Unit-dose hospital packaging.
• Improved moisture protection.
• Simplified excipient labeling.

The commercial case is strongest where the reformulation solves a documented supply, tolerability or medication-safety problem.

4. Global-market localization

Excipient restrictions differ by jurisdiction. A global strategy may require:

• Lactose-free variants.
• Reduced colorant systems.
• Compliance with regional gelatin requirements.
• Country-specific capsule-shell sourcing.
• Different container-closure systems for hot and humid climates.
• Local sterile manufacturing or fill-finish partnerships.

Geographic protection may come from separate formulation, manufacturing-process and device filings. Patent term, regulatory linkage and generic approval rules must be assessed country by country.

How does Dantrium compare with competing dantrolene products?

Criterion	Conventional Dantrium capsule	Traditional IV dantrolene	Rapid-delivery IV competitor
Main value driver	Price and supply	Clinical availability	Preparation speed and workflow
Excipient complexity	Low to moderate	Moderate to high	High
Generic substitution risk	High	Moderate	Depends on formulation rights
Hospital purchasing influence	Moderate	High	High
Patent opportunity	Limited	Moderate	Higher
Manufacturing barrier	Low to moderate	Sterile and lyophilization capability	High
Commercial differentiation	Packaging, tolerability, supply	Stability and availability	Time, volume and convenience

What regulatory pathway applies to a new Dantrium formulation?

A conventional capsule matching the reference product is generally suited to an ANDA. A new formulation that changes excipients but maintains the same active ingredient, dosage form and route may still qualify for an ANDA if it meets sameness and equivalence requirements.

A 505(b)(2) application becomes more relevant where the applicant proposes:

• A new injectable concentration.
• A different reconstitution system.
• A new dosage form.
• A clinically meaningful delivery improvement.
• A new administration route.
• A formulation supported by studies beyond standard bioequivalence.

FDA review will focus on pharmaceutical equivalence, bioequivalence or clinical performance, inactive-ingredient safety, sterility, container closure, stability and labeling.[2]

Key Takeaways

• Dantrium’s active-ingredient exclusivity has expired, leaving conventional capsules exposed to generic competition.
• Oral excipient opportunities are incremental and center on lactose avoidance, capsule size, stability, packaging and supply reliability.
• Intravenous dantrolene offers the stronger commercial opportunity because emergency preparation speed and hospital workflow have direct economic value.
• Mannitol, pH control, lyophilization, container closure and reconstitution volume are the core intravenous formulation variables.
• The most defensible intellectual property is likely to cover rapid reconstitution, reduced-volume delivery, stability, devices and manufacturing processes.
• A conventional capsule is generally an ANDA opportunity; a materially differentiated injectable may support a 505(b)(2) strategy.
• Hospital kits, inventory programs and emergency-readiness services can create commercial differentiation beyond the active ingredient.
• Paragraph IV and litigation exposure depends on current Orange Book listings and product-specific formulation patents, not on the expired original dantrolene rights.

FAQs About Dantrium Excipient Strategy and Commercial Opportunities

Can a lactose-free Dantrium capsule support a separate product opportunity?

Yes, but lactose removal alone may provide limited protection. The commercial case improves if the product addresses documented tolerability, procurement or labeling requirements and is combined with a defensible formulation or packaging strategy.

Why is intravenous dantrolene more commercially attractive than oral Dantrium?

Intravenous dantrolene is used in time-sensitive emergencies. Hospitals value rapid reconstitution, reduced preparation steps, lower vial burden and reliable emergency inventory, creating differentiation that is less available in a conventional oral capsule.

Can mannitol be replaced in an intravenous dantrolene formulation?

Potentially, but replacement would require evaluation of solubility, stability, osmolality, lyophilized-cake structure, reconstitution time, compatibility and safety. The regulatory burden would depend on the extent of formulation and performance differences.

Does a new Dantrium excipient automatically receive patent protection?

No. A patent requires novelty, non-obviousness and adequate disclosure. A routine substitution of one conventional diluent, lubricant or bulking agent may not satisfy those standards without an unexpected technical result.

What is the highest-value commercial feature for a new dantrolene product?

For intravenous use, the highest-value feature is usually a measurable reduction in preparation time and handling burden while preserving stability, safety and reliable dosing. In the capsule market, consistent supply and differentiated packaging are more practical value drivers.

References

1. U.S. Food and Drug Administration. (n.d.). Dantrium dantrolene sodium prescribing information. FDA labeling database.
2. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA guidance and regulatory materials.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.